A US company supports a plan to use Cresper's genetic technology to treat heart disease
The American Biofuels Company seeks to use CRISP medical technology for genetic modification to end heart disease in cooperation with one of the world's leading medical technology companies to make this project a success..
Fareef has revealed that it has managed to raise about $ 58.5 million, most of which were provided by GV (Google Ventures), the financial arm of Google Inc..
Cresper technology is a revolutionary breakthrough in genetic engineering
"Verve has vast and unprecedented potential to address the leading cause of death in the world," said Krishna Wishant, general partner of GF, in a press release.
This comes at a time when scientists are aware that genetic legacies play a pivotal role in determining the risk of heart disease or heart attack .. The plan includes the company (Fairf) the use of Cresper technology for genetic modification among adults with high genetic predisposition to heart disease to form the genes of people low Risk of injury.
"Weak commitment, costs, side effects and limited access have reduced the impact of existing heart medications such as cholesterol-lowering statins," said Seker Kathirizan, the company's new chief executive.
"Our treatment will help change the treatment system for heart disease caused by chronic care, eating cereals daily or monthly injections to reach a one-time treatment approach."
(tagsToTranslate) Genetic Cresper Technology for the Treatment of Heart Disease (t) Health (t) Health News (t) Health
Post a Comment